Patents Assigned to Inserm
  • USE OF AT LEAST ONE CYTOSOLIC PHOSPHOLIPASE A2 INHIBITOR AS A MEDICINE FOR SYMPTOMATIC TREATMENT OF MUCOVISCIDOSIS
    Publication number: 20100093985
    Abstract: A subject of the invention is the use of at least one cytosolic phospholipase A2 (cPLA2) inhibitor in the preparation of a medicament intended for the preventive and/or curative symptomatic treatment of cystic fibrosis, particularly of the increased secretion of mucus in cystic fibrosis.
    Type: Application
    Filed: April 5, 2007
    Publication date: April 15, 2010
    Applicants: INSTITUT PASTEUR, INST NAT DE LA SANTE ET DE LA RECHER. MED (INSERM)
    Inventors: Fariel Dif, Lhousseine Touqui
  • Method of Diagnosis of Tuberculosis Related Immune Restoration Syndrome (IRS)
    Publication number: 20100093007
    Abstract: The present invention relates to a method and kit of diagnosis of Immune Restoration Syndrome associated with tuberculosis (TB-IRS) in patients infected with tuberculosis (TB) as well as in HIV co-infected patients comprising detecting an acute increase in Th1 response following exposure to mycobacterial extract, referred as tuberculin or PPD (Purified Protein Derivative) as well as to the 16 kDa protein, but not to ESAT-6 or CFP-10, two antigens from mycobacterium tuberculosis.
    Type: Application
    Filed: September 7, 2006
    Publication date: April 15, 2010
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Brigitte Autran, Anne Bourgarit, Guislaine Carcelain, Valérie Martinez, Brigitte Gicquel, Daniel Sereni
  • Anaplerotic Therapy of Huntington Disease and Other Polyglutamine Diseases
    Publication number: 20100063147
    Abstract: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.
    Type: Application
    Filed: December 3, 2007
    Publication date: March 11, 2010
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Alexandra Durr, Fanny Mochel
  • LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS
    Publication number: 20100061928
    Abstract: The present invention relates to the use of a compound of formula (I): in which R1 represents a radionuclide, Ar represents an aromatic nucleus, m is an integer varying from 2 to 4, R2 and R3 represent, independently of one another, a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or an aryl group chosen from a phenyl, benzyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, indolyl, indazolyl, furyl and thienyl group, and their addition salts with pharmaceutically acceptable acids, in the preparation of a radiopharmaceutical composition intended for the diagnosis and/or treatment of melanoma.
    Type: Application
    Filed: July 27, 2007
    Publication date: March 11, 2010
    Applicants: Institut National De La Sante et De La Recherche Medicale (INSERM), Universite D'Auvergne Clermont 1
    Inventors: Jean-Claude Madelmont, Jean-Michel Chezal, Nicole Moins, Jean-Claude Teulade, Olivier Chavignon
  • ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS
    Publication number: 20100062987
    Abstract: The present invention pertains to pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one glutamate receptor activating substance.
    Type: Application
    Filed: November 22, 2007
    Publication date: March 11, 2010
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale
    Inventors: Serge Picaud, Jose Sahel, Qinping Wang, Agnes Duboc, Manuel Simonutti
  • Lipophilic compounds and uses thereof
    Patent number: 7667070
    Abstract: The present invention has for an object a cationic lipophilic compound of the following general formula (I): wherein: a) R1 and R?1 each represent, independently from one another, an alkyl chain, an alkenyl chain or a polyalkenyl chain with from 10 to 24 carbon atoms, with the polyalkenyl chain having from 2 to 4 double links; b) R2 is a hydrogen atom or an alkyl chain having from 1 to 4 carbon atoms; and R3 is a group with the following formula (IIa) —(CH2)n— or following formula (IIb) —C(?NH)—NH—(CH2)n— wherein: n is an integer equal to 0, 1, 2, 3 or 4; and d) A+ is an organic cation; e) X? is an anion.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: February 23, 2010
    Assignees: Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante de de la Recherche Medicale (INSERM), Universite de Bretagne Occidentale, Centre Hospitalier Universitaire de Brest
    Inventors: Hervé Des Abbayes, Jean-Jacques Yaouanc, Jean-Claude Clement, Karine Le Ny, Claude Ferec, Tristan Montier, Pascal Delepine
  • ANTI CD44 ANTIBODIES FOR ERADICATING LEUKAEMIC STEM CELLS AND BREAST CANCER STEM CELLS
    Publication number: 20100040540
    Abstract: The present invention provides the use of an anti-CD44 antibody, a (Fab?)2, Fab, Fab? fragment thereof, an IgG or IgM isotype thereof, in a method for eradicating pathological stem cells in cancer therapy, and more specifically in breast cancer and leukaemia therapy.
    Type: Application
    Filed: March 19, 2009
    Publication date: February 18, 2010
    Applicants: Institut National De La Sante et De La Recherche Medicale (INSERM), University Health Network
    Inventors: Florence Smadja, John Dick
  • Use of glucose-6-phosphate isomerase and antibodies thereto for the diagnosis and therapy of arthritis, and test of anti-arthritic compounds
    Patent number: 7662375
    Abstract: The present invention relates to the use of antibodies against glucose-6-phosphate isomerase (GPI) and like protein for diagnosis of arthritis and the use of said protein for treatment of arthritis. It is also aimed at a process for isolating monoclonal antibodies capable of transferring arthritis and antibodies thereof, as well as a method for determining the anti-arthritis potential of a composition.
    Type: Grant
    Filed: February 24, 2006
    Date of Patent: February 16, 2010
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Christophe Benoist, Isao Matsumoto, Anne-Sophie Korganow, Diane Mathis, Mariana Maccioni, Hong Ji
  • COMPOSITIONS COMPRISING A SIRNA AND LIPIDIC 4,5-DISUBSTITUTED 2-DEOXYSTREPTAMINE RING AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF
    Publication number: 20100035974
    Abstract: The present invention relates to a composition comprising a siRNA and a transfecting compound consisting of an aminoglycoside of the class of 4,5-disubstituted 2-deoxystreptamine ring linked via a spacer molecule to a lipid moiety of formula —(R1)R2 wherein R1 and R2 represent, independently of one another, a hydrogen atom or a fatty aliphatic chain or R1 or R2 is absent, with the proviso that at least one of R1 and R2 represents a fatty aliphatic chain; or —OR3 or —NR3 wherein R3 represents a steroidal derivative. The invention also concerns in vitro and in vivo applications of these compositions.
    Type: Application
    Filed: October 4, 2007
    Publication date: February 11, 2010
    Applicants: Centre National De La Recherche Scientifique (CNRS, Institut National De La Sante Et De La Recherche Medicale (INSERM)
    Inventors: Jean-Marie Lehn, Jean-Pierre Vigneron, Pierre Lehn, Bruno Pitard
  • Vaccine composition comprising an immunoadjuvant compound consisting of a Rho GTPase family activator
    Patent number: 7655240
    Abstract: This invention is based on the experimental finding that activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine. This invention concerns a vaccine composition including an immunoadjuvant compound, wherein the immunoadjuvant compound consists of a Rho GTPase activator.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: February 2, 2010
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Emmanuel Lemichez, Cécil Czerkinsky, Fabienne Anjuere, Patrice Boquet, Patrick Munro, Gilles Flatau
  • METHODS FOR TREATING LATENT TUBERCULOSIS
    Publication number: 20100022504
    Abstract: A method for treating individuals affected with latent tuberculosis comprising a step of administering an effective amount of one or more carbapenem compounds to the said individuals.
    Type: Application
    Filed: July 28, 2008
    Publication date: January 28, 2010
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: JEAN-LUC MAINARDI, MICHEL ARTHUR, LAURENT GUTMANN, MARIE LAVOLLAY
  • Method for screening agents capable of treating obesity
    Patent number: 7651844
    Abstract: The invention concerns a method for screening agents capable of treating, by way of prevention or cure, obesity or one of the disorders associated with obesity by modulating the expression of the SPARC protein or of its activity. The invention also concerns a method for diagnosing obesity or one of the disorders associated with obesity by monitoring the expression rate of the SPARC protein or its activity. The invention further concerns a composition comprising an agent modulating the expression of the SPARC protein or its activity. The invention finally concerns the use of any agent modulating the expression of the SPARC protein or its activity for preparing a pharmaceutical composition for treating, by way of prevention or cure, obesity or one of the disorders associated with obesity.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: January 26, 2010
    Assignees: Merck Sante, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Sophie Tartare-Deckert, Emmanuel Van Obberghen
  • Compounds Regulating Calreticulin, KDEL Receptor and/or ERP-57 Cell Surface Exposure and Uses Thereof to Evaluate the Efficiency of a Cancer Treatment
    Publication number: 20100015653
    Abstract: The present invention relates to a method for determining the susceptibility of a patient tumour cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumour cell.
    Type: Application
    Filed: September 7, 2007
    Publication date: January 21, 2010
    Applicants: Institut Gustave Roussy, Inserm (Institut National De La Sante Et De La Recherche Medicale)
    Inventors: Guido Kroemer, Laurence Zitvogel, Theocharis Panaretakis
  • Inhibitors of Protein Phosphatase 1, GADD34 and Protein Phosphatase 1/GADD34 Complex, Preparation and Uses Thereof
    Publication number: 20100016235
    Abstract: The present invention relates to the use of a protein phosphatase inhibitor selected from an inhibitor of the catalytic subunit of the protein phosphatase 1 (PP1), an inhibitor of GADD34 and an inhibitor of the PP1/GADD34 complex to prepare a pharmaceutical composition to prevent or treat a cancer in a mammal, wherein the pharmaceutical composition is intended for administration in combination with a product used in a treatment of a cancer.
    Type: Application
    Filed: September 7, 2007
    Publication date: January 21, 2010
    Applicants: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Guido Kroemer, Laurence Zitvogel
  • USE OF SOLUBLE CD160 TO SUPPRESS IMMUNITY
    Publication number: 20100008932
    Abstract: Pharmaceutical composition including a soluble form of CD160 for treating an inflammatory condition involving an undesired immune response, such as tissue graft or organ rejection, and autoimmune diseases; in vitro method for screening an individual for the presence of an inflammatory condition such as infectious and autoimmune diseases, tissue graft and organ rejection, or the presence of a tumor or activated endothelial cells, or for monitoring therapy of an inflammatory condition such as an autoimmune disorder or a tissue or organ rejection, or a tumor during chemotherapy including treatment with an anti-angiogenic substance or antibody.
    Type: Application
    Filed: July 18, 2007
    Publication date: January 14, 2010
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Armand Bensussan, Laurence Boumsell, Nicolas Ortonne
  • Method for Expanding Monocytes
    Publication number: 20100003272
    Abstract: The invention relates to an ex vivo method for expanding monocytes, macrophages or dendritic cells, which method comprises inhibiting the expression or the activity of MafB and c-Maf in monocytes, macrophages or dendritic cells; and expanding the cells in the presence of at least one cytokine or an agonist of cytokine receptor signaling.
    Type: Application
    Filed: January 10, 2008
    Publication date: January 7, 2010
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventor: Michael Sieweke
  • Non-Invasive, Prenatal, In-Vitro Method for Detecting the Normal Healthy Condition, the Condition of a Healthy Carrier or the Condition of a Carrier Inflicted with Cystic Fibrosis
    Publication number: 20090317797
    Abstract: The invention relates to a non-invasive, prenatal, in-vitro method for detecting the normal healthy condition, the condition of a healthy carrier or the condition of a carrier inflicted with cystic fibrosis, from the fetal cell(s) from a maternal sample, comprising the DNA of an individual to be tested. The invention also relates to oligonucleotide primers and to their use within the scope of a non-invasive, prenatal, in-vitro method for detecting the condition of a healthy carrier or of a carrier inflicted with cystic fibrosis.
    Type: Application
    Filed: January 18, 2006
    Publication date: December 24, 2009
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIC-HOPITAUX DE PARIS, UNIVERSITE RENE DESCARTES PARIS V
    Inventors: Patrizia Paterlini, Jean-Paul Bonnefont, Isabelle Desitter, Ali Saker
  • NUCLEIC ACIDS FOR EXPRESSING A POLYNUCLEOTIDE OF INTEREST IN MAMMALIAN CANCER CELLS
    Publication number: 20090318540
    Abstract: The invention relates to regulatory polynucleotides derived (i) from rat and human AFP promoter sequences and (ii) from rat and human HIP/PAPI promoter sequences, which regulatory polynucleotides are useful for expressing nucleic acids of interest specifically in mammalian cancer cells, including mammalian cancer liver cells.
    Type: Application
    Filed: September 12, 2007
    Publication date: December 24, 2009
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Jamilla Faivre, Julie Herve, Jérôme Clerc, Christian Brechot
  • Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2
    Publication number: 20090317401
    Abstract: The present invention relates to biological and medical application of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) an of the conservative equivalents thereof.
    Type: Application
    Filed: August 9, 2005
    Publication date: December 24, 2009
    Applicant: INSERM
    Inventors: Armand Bensussan, Laurence Boumsell, Philippe Le Bouteiller
  • Mononucleotide repeats microsatellite markers for detecting microsatellite instability
    Publication number: 20090317815
    Abstract: A method for evaluating microsatellite instability associated with a tumour, which entails the steps of amplifying microsatellite loci in a biological sample containing genomic DNA from the tumour and determining sizes of DNA amplification products, wherein at least one microsatellite locus selected from the group consisting of NR 21, NR 22, NR 24 and NR 27, is amplified.
    Type: Application
    Filed: March 30, 2009
    Publication date: December 24, 2009
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE-INSERM
    Inventors: Richard Hamelin, Nirosha Suraweera